PT  - JOURNAL ARTICLE
AU  - Duan, Kai
AU  - Liu, Bende
AU  - Li, Cesheng
AU  - Zhang, Huajun
AU  - Yu, Ting
AU  - Qu, Jieming
AU  - Zhou, Min
AU  - Chen, Li
AU  - Meng, Shengli
AU  - Hu, Yong
AU  - Peng, Cheng
AU  - Yuan, Mingchao
AU  - Huang, Jinyan
AU  - Wang, Zejun
AU  - Yu, Jianhong
AU  - Gao, Xiaoxiao
AU  - Wang, Dan
AU  - Yu, Xiaoqi
AU  - Li, Li
AU  - Zhang, Jiayou
AU  - Wu, Xiao
AU  - Li, Bei
AU  - Xu, Yanping
AU  - Chen, Wei
AU  - Peng, Yan
AU  - Hu, Yeqin
AU  - Lin, Lianzhen
AU  - Liu, Xuefei
AU  - Huang, Shihe
AU  - Zhou, Zhijun
AU  - Zhang, Lianghao
AU  - Wang, Yue
AU  - Zhang, Zhi
AU  - Deng, Kun
AU  - Xia, Zhiwu
AU  - Gong, Qin
AU  - Zhang, Wei
AU  - Zheng, Xiaobei
AU  - Liu, Ying
AU  - Yang, Huichuan
AU  - Zhou, Dongbo
AU  - Yu, Ding
AU  - Hou, Jifeng
AU  - Shi, Zhengli
AU  - Saijuan, Chen
AU  - Chen, Zhu
AU  - Zhang, Xinxin
AU  - Yang, Xiaoming
TI  - The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study
AID  - 10.1101/2020.03.16.20036145
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.16.20036145
4099  - http://medrxiv.org/content/early/2020/03/23/2020.03.16.20036145.short
4100  - http://medrxiv.org/content/early/2020/03/23/2020.03.16.20036145.full
AB  - Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65×109/L vs. 0.76×109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.Significance Statement COVID-19 is currently a big threat to global health. However, no specific antiviral agents are available for its treatment. In this work, we explored the feasibility of convalescent plasma (CP) transfusion to rescue severe patients. The results from 10 severe adult cases showed that one dose (200 mL) of CP was welltolerated and could significantly increase or maintain the neutralizing antibodies at a high level, leading to disappearance of viremia in 7 days. Meanwhile, clinical symptoms and paraclinical criteria rapidly improved within 3 days. Radiological examination showed varying degrees of absorption of lung lesions within 7 days. These results indicate that CP can serve as a promising rescue option for severe COVID-19 while the randomized trial is warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000030048Funding StatementThis study was funded by Key projects of the Ministry of Science and Technology China “Preparation of specific plasma and specific globulin from patients with a recovery period of COVID-19 infection” (project number: 2020YFC0841800).This work was also supported by Shanghai Guangci Translational Medicine Development Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with the manuscript were available on request